The Psychedelics Newsletter

The cost-benefit of MDMA-assisted therapy, quantitative data in psychedelic therapy, European regulators urged to reschedule psychedelic medicine

Psychedelic-assisted therapy for harmful gambling, EU regulators promote psychedelic medicine, PAREA campaigns for psychedelic healthcare in Europe.

Psychedelic medicines rescheduled in Australia, Awakn granted innovation passport for ketamine therapy, Psyched Wellness releases Amanita muscaria extract.

Psilocybin reduces binge eating episodes, DMT-assisted therapy for major depressive disorder, Psilocybin trial with 160 patients in Australia.

The UK’s emerging psychedelic healthcare industry, Two thirds of Canadians support psilocybin legalisation, Education to normalise psychedelic healthcare.

Awakn’s expansion across the Atlantic, Psychedelic-assisted therapy for gambling addiction, Psychedelic medicines in the treatment of TBI.

Shares in atai down 90% since IPO, Psychedelic healthcare for eating disorders, Decriminalisation bill filed in New York.

Best-read articles of 2022, Psychedelic healthcare valued at £542 million, Oregon Psilocybin Services accepting applications.

Beckley Psytech and 5-MeO-DMT, Quebec reimburses cost of psychedelic healthcare, The rise of psychedelic research in the UK.

2022: Six significant inflection points, UK government to fund Phase III ketamine study, German government funds psilocybin study.

COMPASS Pathways and the economic outlook for 2023, DEA announces psychedelic medicine production quotas, Oregon’s psilocybin programme and therapist training.

The Psychedelics as Medicine Report: Fourth Edition, Psychedelic drugs and the mental health crisis, Rise in long-term sickness a threat to UK economy.